Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company achieved a revenue of 6.08 billion in 2024, a year-on-year increase of 8.6%, and a net profit attributable to shareholders of 921 million, up 1.2% year-on-year [5][6] - The company is expected to continue its growth trajectory with projected net profits of 996 million, 1.08 billion, and 1.17 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 8.2%, 8.8%, and 8.1% [4][5] Revenue and Profitability - The company reported a significant increase in Q4 non-recurring profit, growing by 53%, driven by improved operational efficiency and reduced expense ratios [1] - The life sciences segment generated revenue of 2.84 billion, a 14% increase, with a gross margin of 50.4%, up 2.5 percentage points year-on-year [2] - The industrial testing segment achieved revenue of 1.2 billion, a 10% increase, with a gross margin of 45.3%, up 1.7 percentage points [2] - The trade assurance segment reported revenue of 760 million, a 9% increase, with a gross margin of 71.2%, up 6.6 percentage points [2] - The consumer products testing segment had revenue of 990 million, a 0.9% increase, with a gross margin of 43.5%, down 1.2 percentage points [2] - The medical segment faced a decline, with revenue of 290 million, down 15%, and a gross margin of 20.4%, down 19 percentage points [2] Cash Flow and Capital Expenditure - The company maintained strong operating cash flow with a net inflow of 1.06 billion in 2024, consistent with the previous year, and a net cash inflow of 790 million in Q4 [3] - Capital expenditure for the year was 690 million, representing 11% of revenue, with a focus on traditional business and new project investments [3] Strategic Initiatives - The company is accelerating its AI technology applications, with 15 pilot projects initiated by the end of 2024, focusing on defect detection and intelligent scheduling [4] - The company is actively pursuing strategic acquisitions in emerging sectors, including 100% stakes in companies in Greece and Hong Kong, enhancing its international presence [4]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company achieved a revenue of 6.08 billion in 2024, representing an 8.6% year-on-year growth, with a net profit attributable to shareholders of 921 million, up 1.2% year-on-year [5][6] - The company is focusing on digital transformation and AI technology applications, with 15 AI application pilot projects initiated by the end of 2024 [4] - The company is actively pursuing strategic acquisitions in emerging sectors, including 100% stakes in NAIAS in Greece and Dahu Asia Pacific in Hong Kong [4] Summary by Sections Financial Performance - In Q4, the company reported a significant increase in non-recurring profit, growing by 53%, driven by improved operational efficiency and reduced expense ratios [1] - The company’s revenue for 2024 was 60.8 billion, with a quarterly breakdown of 12 billion in Q1, 16 billion in Q2, 16 billion in Q3, and 17 billion in Q4 [1] - The overall gross margin for 2024 improved to 49.5%, a 1.4 percentage point increase year-on-year [2] Business Segments - Life Sciences segment revenue reached 2.84 billion, up 14%, with a gross margin of 50.4% [2] - Industrial Testing segment revenue was 1.2 billion, up 10%, with a gross margin of 45.3% [2] - Trade Assurance segment revenue was 760 million, up 9%, with a gross margin of 71.2% [2] - Consumer Products Testing segment revenue was 990 million, up 0.9%, with a gross margin of 43.5% [2] - Pharmaceutical segment revenue was 290 million, down 15%, with a gross margin of 20.4% [2] Cash Flow and Capital Expenditure - The company reported a net cash inflow of 1.06 billion from operating activities in 2024, maintaining a net cash ratio of 115% [3] - Capital expenditure for the year was 690 million, accounting for 11% of revenue, with a focus on traditional and new projects [3] Future Outlook - The company forecasts net profits of 996 million, 1.084 billion, and 1.171 billion for 2025, 2026, and 2027 respectively, with expected growth rates of 8.2%, 8.8%, and 8.1% [4][5]

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company's revenue growth is stable, with government subsidies and other non-operating factors impacting net profit. In 2024, the company achieved total revenue of 6.1 billion yuan, a year-on-year increase of 9%, and a net profit of 920 million yuan, a year-on-year increase of 1%. The non-recurring profit decreased by 0.65 million yuan due to reduced government subsidies [2] - The gross margin is steadily increasing, with significant results from lean management. In 2024, the company's gross margin was 49.5%, up 1.4 percentage points year-on-year, while the net profit margin was 15.3%, down 1.2 percentage points year-on-year [3] - The company is well-positioned for long-term growth due to its forward-looking, diversified layout, and international strategy. The company is expanding into new markets such as pet food and renewable energy, and enhancing its overseas presence through acquisitions [4] Revenue and Profit Forecast - The company forecasts total revenue of 6.1 billion yuan for 2024, with a net profit of 921 million yuan. The projected net profit for 2025 is adjusted to 1.06 billion yuan, with a corresponding P/E ratio of 18 [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 （二）内部控制环境 1、治理结构 公司按照《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证券交易所上市公司自律监 管指引第2号一一创业板上市公司规范运作》等法律、行政法规、部门规章的要求，建立了规范的公司 治理结构和科学的议事规则，制定了符合公司发展要求的各项制度和程序，明确决策、执行、监督等方 面的职责权限，形成了科学有效的职责分工和制衡机制。股东大会、董事会、监事会分别按其职责行使 决策权、执行权和监督权。股东大会享有法律法规和公司章程规定的合法权利，依法行使对公司经营方 针、筹资、投资、利润分配等重大事项的决定权。 董事会对股东大会负责，依法行使企业的经营决策权。董事会7名董事中，有3名独立董事。独立董事担 任审计委员会、薪酬考核与提名委员会专门委员会的召集人，专门委员会可对涉及专业领域的事项进行 事前审核，以利于独立董事更好地发挥作用。 每年集团总部财务对分、子公司财务进行会计基础工作检查，内审部对法人治理、廉洁文化建设、信息 安全、内部控制等情况进行检查监督。管理层根据董事会的授权，负责组织实施股东大会、董事会决议 事项，主持企业日常经营 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300012 证券简称：华测检测 公告编号：2025-019 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经过审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 公司报告期末至季度报告披露日股本是否因发行新股、增发、配股、股权激励行权、回购等原因发生变 化且影响所有者权益金额 √是 □否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 （三） 主要会计数据和财务指标发生变动的情况及原因 √适用 □不适用 1、资产负债表重大变化情况 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符 ...

2024 年和2025 年一季度营收均保持稳健增长，彰显综合性检测机构的韧性。2024 年公司全年营收同比 增8.6%。分业务看：1）生命科学（环境检测+食品检测）：营收28.4 亿元，同比增13.75%；土壤三普 进入收入兑现期带来增量，新增长点海洋环境、环境监测表现亮眼，食农检测创新驱动成长；2）工业 测试：营收12.0 亿元，同比增10.32%；建工检测业务升级，毛利率提升明显，船舶、计量、数字化持 续布局，双碳和ESG 领域逐步获得新资质；3）消费品测试：营收9.88 亿元，同比增0.88%;受到医疗器 械产品线重分类及蔚思博产能爬坡影响，增速较慢，但轻工纺织增长较好，电子科技、汽车稳定增长， 大交通赛道积极布局中，加码投资FA、MA，加快芯片半导体业务转型升级；4）贸易保障：营收7.64 亿元，同比增9.19%；保持细分赛道竞争优势，提升实验室效率，开拓海外客户；5）医药医学：营收 2.87 亿元，同比下降14.71%；子公司华测品创全年净利润亏损约0.67 亿元；医疗整治专项行动影响需 求释放，但2023 年公司通过收购进入的药学CMC 研究、医疗器械领域发展趋势良好。 事件描述 华测检测发布20 ...

Investment Rating - The investment rating for the company is "Buy" and it is maintained [7]. Core Views - The company has demonstrated resilient growth with a revenue increase of 8.6% year-on-year, reaching 6.08 billion yuan in 2024. The net profit attributable to shareholders rose by 1.2% to 0.921 billion yuan, while the non-recurring net profit increased by 9.8% to 0.860 billion yuan [2][6]. - In Q1 2025, the company achieved a revenue of 1.287 billion yuan, reflecting an 8.0% year-on-year growth, with a net profit of 0.136 billion yuan, up 2.8% [2][6]. Summary by Sections Financial Performance - For 2024, the company reported a total revenue of 60.8 billion yuan, with a year-on-year growth of 8.6%. The net profit attributable to shareholders was 9.21 billion yuan, a 1.2% increase, and the non-recurring net profit was 8.60 billion yuan, up 9.8% [2][6]. - In Q1 2025, the company recorded a revenue of 12.87 billion yuan, an 8.0% increase year-on-year, with a net profit of 1.36 billion yuan, reflecting a 2.8% growth [2][6]. Business Segments - The revenue from the Life Sciences segment (including environmental and food testing) was 2.84 billion yuan, a 13.75% increase. The Industrial Testing segment generated 1.20 billion yuan, up 10.32%. The Consumer Products Testing segment saw revenue of 0.988 billion yuan, a modest increase of 0.88%. The Trade Assurance segment achieved 0.764 billion yuan, a 9.19% growth. However, the Medical and Pharmaceutical segment experienced a decline of 14.71%, with revenue of 0.287 billion yuan [6][10]. Profitability Metrics - The company’s non-recurring net profit margin for 2024 was 14.14%, a slight increase of 0.16 percentage points. The overall gross margin improved to 49.5%, up 1.42 percentage points, indicating strong competitive advantages and internal control capabilities [10]. - In Q1 2025, the gross margin was 46.3%, reflecting a year-on-year increase of 0.99 percentage points, while the non-recurring net profit margin improved by 0.27 percentage points [10]. Future Outlook - The company forecasts revenues of 65.21 billion yuan, 71.91 billion yuan, and 79.21 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 7.18%, 10.28%, and 10.15%. The net profit attributable to shareholders is expected to reach 10.14 billion yuan, 11.43 billion yuan, and 12.87 billion yuan over the same period, with corresponding growth rates of 10.1%, 12.6%, and 12.7% [10].

Core Viewpoint - The company Huace Testing announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 1 yuan per share (before tax), totaling approximately 167 million yuan, which represents 18.16% of its net profit [2]. Group 1: Dividend Distribution - The proposed cash dividend for 2024 is 1 yuan per share, with a total cash payout of 167 million yuan [2]. - This marks the 17th cumulative cash distribution since the company's listing [2]. - The dividend yield for 2024 is 0.78%, an increase from 0.55% in 2023 [2]. Group 2: Financial Performance - For the fiscal year 2024, the company reported total revenue of 6.084 billion yuan, reflecting a year-on-year growth of 8.55% [2]. - The net profit for the same period was 921 million yuan, showing a year-on-year increase of 1.19% [2]. - The basic earnings per share (EPS) is reported at 0.55 yuan, with a weighted average return on equity (ROE) of 14.07% [2]. Group 3: Market Activity - The stock experienced a net outflow of 26.28 million yuan in principal funds today, with a total net outflow of 53.89 million yuan over the past five days [3]. - The latest margin financing balance for the stock is 564 million yuan, which has increased by 45.23 million yuan, representing an 8.72% rise over the past five days [4]. Group 4: Industry Comparison - Among the 22 companies in the social services sector that announced their 2024 dividend plans, Huace Testing's cash payout ranks fifth, with the highest being 548 million yuan from Foreign Service Holdings [4]. - The cash payout of Huace Testing accounts for 18.16% of its net profit, which is relatively moderate compared to other companies in the sector [4].

Beijing Dehao International Certified PublicAccountants(Limited Liability Partnership) 华测检测认证集团股份有限公司 审计报告及财务报表 德皓审字[2025]00000808号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) 审计报告 华测检测认证集团股份有限公司 （2024年 1 月 1 日至 2024年 12月 31日止） | | 目 | 录 | 页 | 次 | | --- | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | | 二、 | 已审财务报表 | | | | | | 合并资产负债表 | | 1-2 | | | | 合并利润表 | | 3 | | | | 合并现金流量表 | | 4 | | | | 合并股东权益变动表 | | 5-6 | | | | 母公司资产负债表 | | 7-8 | | | | 母公司利润表 | | 9 | | | | 母公司现金流量表 | | 10 | | | | 母公司股东权益变动表 | | 11-12 | | ...

华测检测认证集团股份有限公司 内部控制审计报告 德皓内字[2025]00000037 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 华测检测认证集团股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 内 部 控 制 审 计 报 告 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 德皓内字[2025]00000037 号 华测检测认证集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了华测检测认证集团股份有限公司（以下简称华测 检测）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控 ...